Averion expands European operations
US-based Averion International, a clinical research organisation (CRO) specialising in oncology, medical devices, dermatology and nephrology, is opening four European-based offices.
US-based Averion International, a clinical research organisation (CRO) specialising in oncology, medical devices, dermatology and nephrology, is opening four European-based offices.
The Massachusetts company has taken on new staff, including clinicians with oncology clinical trial experience, to support its expanded European operations.
The new Averion offices include: Averion Europe GmbH, located near Frankfurt, Germany, Averion Ltd., located in the UK, Averion Clinical Research GmbH, located in Austria, and Averion Sp. z.o.o., located in Poland.
John Shillingford, president of Averion Europe said: "We expect this expansion will open new opportunities for Averion as it allows us to gain access in Central and Eastern Europe to large populations of patients. We have already identified clinical sites within Europe with competent, well-trained staff to run quality trials at competitive prices."
The international company says it has supported 51 FDA approvals to date with no refusals among submissions accepted for filing and has helped achieve approvals for 12 oncology-related products.